Active and passive vaccination against hantavirus pulmonary syndrome with Andes virus M genome segment-based DNA vaccine.
about
Animal Models for the Study of Rodent-Borne Hemorrhagic Fever Viruses: Arenaviruses and HantavirusesThe Syrian hamster model of hantavirus pulmonary syndromeAntiviral Biologic Produced in DNA Vaccine/Goose Platform Protects Hamsters Against Hantavirus Pulmonary Syndrome When Administered Post-exposureRodent-borne diseases and their risks for public healthA global perspective on hantavirus ecology, epidemiology, and diseaseDNA vaccine-generated duck polyclonal antibodies as a postexposure prophylactic to prevent hantavirus pulmonary syndrome (HPS)Hantavirus infections for the clinician: from case presentation to diagnosis and treatment.Pathophysiology of hantavirus pulmonary syndrome in rhesus macaques.Highly differentiated, resting gn-specific memory CD8+ T cells persist years after infection by andes hantavirus.A novel Sin Nombre virus DNA vaccine and its inclusion in a candidate pan-hantavirus vaccine against hantavirus pulmonary syndrome (HPS) and hemorrhagic fever with renal syndrome (HFRS).A hantavirus pulmonary syndrome (HPS) DNA vaccine delivered using a spring-powered jet injector elicits a potent neutralizing antibody response in rabbits and nonhuman primates.Maternally derived recombinant human anti-hantavirus monoclonal antibodies are transferred to mouse offspring during lactation and neutralize virus in vitroRecent approaches in hantavirus vaccine development.Pneumonitis in Syrian golden hamsters (Mesocricetus auratus) infected with Rio Mamoré virus (family Bunyaviridae, genus Hantavirus)Treatment of hantavirus pulmonary syndromeFusion with extracellular domain of cytotoxic T-lymphocyte-associated-antigen 4 leads to enhancement of immunogenicity of Hantaan virus DNA vaccines in C57BL/6 mice.Vesicular stomatitis virus-based vaccine protects hamsters against lethal challenge with Andes virus.Human pathogenic hantaviruses and prevention of infectionDevelopment of a novel plaque reduction neutralisation test for hantavirus infectionNeutralizing antibodies in survivors of Sin Nombre and Andes hantavirus infection.Temporal analysis of Andes virus and Sin Nombre virus infections of Syrian hamstersDemand for nonhuman primate resources in the age of biodefense.Protective effects of a Modified Vaccinia Ankara-based vaccine candidate against Crimean-Congo Haemorrhagic Fever virus require both cellular and humoral responsesEpidermal delivery of protein and DNA vaccines.Immune serum produced by DNA vaccination protects hamsters against lethal respiratory challenge with Andes virus.Construction and nonclinical testing of a Puumala virus synthetic M gene-based DNA vaccine.Genetic immunization with Hantavirus vaccine combining expression of G2 glycoprotein and fused interleukin-2Macaque models of human infectious disease.Adenovirus vectors expressing hantavirus proteins protect hamsters against lethal challenge with andes virus.Antiviral efficacy of favipiravir against two prominent etiological agents of hantavirus pulmonary syndrome.A recombinant pseudotyped lentivirus expressing the envelope glycoprotein of hantaan virus induced protective immunity in mice.A lethal disease model for hantavirus pulmonary syndrome in immunosuppressed Syrian hamsters infected with Sin Nombre virus.Epidemiology of Hantavirus infections in humans: a comprehensive, global overview.Knowledge, attitudes, and practices regarding hantavirus disease and acceptance of a vaccine trial in rural communities of southern Chile.DNA vaccine-derived human IgG produced in transchromosomal bovines protect in lethal models of hantavirus pulmonary syndrome.The use of chimeric virus-like particles harbouring a segment of hantavirus Gc glycoprotein to generate a broadly-reactive hantavirus-specific monoclonal antibody.Induction of protective immunity in a Syrian hamster model against a cytopathogenic strain of Andes virus.Using MODIS satellite imagery to predict hantavirus risk
P2860
Q26798695-45A8AFAE-DD01-407A-813C-8BA31D0DAD92Q27027405-46294115-AB3C-471F-A287-C6201C8A6BD7Q27304441-689458D0-0F48-4EC2-8DF9-A3E7F4C5697CQ28249580-E40F9CDD-F4C5-4EB7-B2A3-73DDD91EFFCCQ28279096-89B4694E-FEFE-4E31-AD4B-CD0A2D803DD4Q28730275-696E344A-0A14-420B-B90A-5D3AF37CA8EFQ33401056-48510870-56D6-4225-AC7D-D00B78F92CB5Q33414924-A74A2AA9-3404-49B1-99B5-0BC9743B468DQ33533293-77F6E47E-D7FD-4A0D-8E8B-8AC11211027DQ33567784-0B7BA860-CBC9-43A5-A73D-69299C8F453AQ34165062-E59C0D40-0CB4-4C4C-B64E-11CF2A7C31B9Q34546010-2BC48E51-BC66-4F10-BED1-9DD16BCBB493Q34602147-0F156F5C-8B35-4E04-B200-EFD760047D0CQ34610482-B24B6988-CB5F-411D-998D-B12C1851ED52Q34727873-4B37C8A2-AF77-4E21-B464-A8C8140B774BQ35478235-B8108E9E-A320-4C32-BA36-894E87201F78Q35531542-57632CFE-0623-4604-9077-8018E23F8B48Q35558535-51C24431-6105-4426-938D-05BAABA952EAQ35680078-C07B1CE1-E9E6-446D-945A-B727BAFB11D2Q35793787-FBD9F003-3931-4F5F-8E62-AE963BE1C4D0Q35914518-BE4A5934-AB88-4299-AD3B-B5FED2894249Q36006282-4CA425E1-F0A5-4F79-9ABB-C666C2AA27FEQ36044109-CCE795FD-C294-42D6-A802-D4AB87C2FDCDQ36316708-4B7C1EA2-0777-48CB-BB23-179157426A44Q36424202-9A42D832-3646-47F6-B20B-4DEA0C8CBE18Q36606789-6577D8B2-1E57-4B81-A1D3-80CD1983D397Q36958845-41EFC208-B83B-4ABD-A688-B6CE3ED10B7BQ37103536-078C2DA7-F769-4BDC-9667-A910BBE4C65DQ37247930-8B65C5A9-F591-44AA-B759-D752A8069AD0Q37263923-F7031BAC-27C0-403B-8FDC-612578288C0FQ37365029-F4221C5B-D4F9-405F-B349-D71264B38E0EQ37547578-C0C958D5-ED48-4ADE-B5D4-035986E3C55AQ38100820-B9EC94BF-8F12-44B0-8A2A-BA62EB344D90Q38796792-2D71B587-6CCC-4AEE-96D2-46605722623CQ41646078-09054C4D-2E1E-4DDA-B821-6D89EEC570EAQ41989325-970BCA49-F662-4456-B986-236242DFA8EFQ45361624-0DADF1AF-E476-46AA-8CAD-BE9CF1DBAC69Q58407924-DA2C7FB3-33E5-47DA-A749-161643DC7F63
P2860
Active and passive vaccination against hantavirus pulmonary syndrome with Andes virus M genome segment-based DNA vaccine.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh
2003年學術文章
@zh-hant
name
Active and passive vaccination ...... ome segment-based DNA vaccine.
@ast
Active and passive vaccination ...... ome segment-based DNA vaccine.
@en
type
label
Active and passive vaccination ...... ome segment-based DNA vaccine.
@ast
Active and passive vaccination ...... ome segment-based DNA vaccine.
@en
prefLabel
Active and passive vaccination ...... ome segment-based DNA vaccine.
@ast
Active and passive vaccination ...... ome segment-based DNA vaccine.
@en
P2093
P2860
P1433
P1476
Active and passive vaccination ...... ome segment-based DNA vaccine.
@en
P2093
C S Schmaljohn
D M Custer
E Thompson
J W Hooper
T G Ksiazek
P2860
P304
P356
10.1128/JVI.77.18.9894-9905.2003
P407
P577
2003-09-01T00:00:00Z